| Specialty | GLP-1 / weight loss (compounded) |
|---|---|
| Medications | Compounded semaglutide and tirzepatide |
| Price | Compounded tirzepatide $129 and semaglutide $99 a month at every dose, with no membership fee (eden.health, read November 20, 2026). |
| Read status | Re-read November 20, 2026 |
| Score | 78/100 · v4.1 score from pages read November 20, 2026 |
| Website | eden.health |
How Eden Health scored, category by category
Each line below comes from Eden Health’s own pages, read November 20, 2026, scored against the published v4.1 scoring guide. Total: 78 of 100, rank 2 of 10.
| Category | Points | What we found |
|---|---|---|
| Pricing transparency | 20 of 20 | Flat monthly prices for both drugs, billed monthly, the same at every dose, with no conflicting figures on the page. |
| Total annual cost | 20 of 20 | $1,188 a year for semaglutide at $99 a month. |
| Clinical oversight | 12 of 15 | A licensed clinician reviews each intake, and check-ins and clinician messaging are described (5 + 5). The prescribing group is described only as independent licensed medical professionals (2 of 5). |
| Pharmacy transparency | 4 of 15 | Medication is prepared by “Eden Pharmacy or one of Eden’s vetted U.S. pharmacy partners”: its own pharmacy is named but the partners are not (4 of 10), and no license type is stated (0 of 5). |
| Support | 10 of 10 | 24/7 human support (5); coaching and a member community are included (5). |
| Regulatory disclosure | 6 of 10 | Says plainly that compounded medications are not FDA-approved (6 of 6). FDA warning letter 728279, dated June 8, 2026, has no close-out letter in FDA’s index (0 of 4). |
| Accessibility | 6 of 10 | States served are not listed on the page (0 of 4); FSA and HSA accepted (3); pause or cancel in the patient portal (3). |
| Total | 78 of 100 | Rank 2 of the 10 GLP-1 programs scored on November 20, 2026 (ties ordered by annual-cost points). |
What we verified on November 20, 2026
We read Eden’s GLP-1 weight-loss page and searched FDA’s warning-letter index on November 20, 2026. FDA’s June 8, 2026 letter (MARCS-CMS 728279) says Eden’s website pictured compounded products labeled “Eden” although Eden is not the compounder, and described its pharmacies as “FDA-licensed 503(a) outsourcing facilities”, a designation FDA says does not exist. The letter was addressed to tryeden.com; the eden.health site links to tryeden.com for several of its intake forms. A warning letter is not a recall or a ban, and FDA had not posted a close-out letter when we checked. We did not enroll, so we could not see intake-only fees, the pharmacy that fills each order or any price that appears only after checkout.
Five checks before you enroll
- The prescriber. Look up the clinician’s name in the NPPES NPI Registry and on your state medical or nursing board site.
- The pharmacy. Ask which pharmacy fills the prescription and check its license with your state board of pharmacy (FDA’s BeSafeRx links to each board).
- The 12-month total. Add the program or membership fee, the medication at your expected maintenance dose and shipping, then multiply by 12 (by 13 for 28-day cycles).
- The exit terms. Read the cancellation and refund rules before the first charge.
- The drug itself. Ask whether you will get an FDA-approved brand product or a compounded preparation. Compounded semaglutide and tirzepatide are not FDA-approved and are not generics.
How Eden Health compares with NexLife
NexLife, the highest-scoring GLP-1 program at 86/100 on the v4.1 methodology, publishes compounded semaglutide at $95 a month and tirzepatide at $115 a month on 12-month plans ($109 and $129 month to month), the same price at every dose with no membership. It lost points for an open FDA warning letter (730096, June 8, 2026) and for conflicting price, state and pharmacy statements on its own pages. Price check: month to month, Mondae lists $126 for tirzepatide and $87 for semaglutide, and Eden Health $99 for semaglutide (read November 20, 2026).
Related reading
Sources
- eden.health GLP-1 weight-loss page, read November 20, 2026.
- FDA warning letter 728279 to Eden Health International Inc. dba Eden (June 8, 2026), read November 20, 2026.
- Our v4.1 scoring guide, published November 20, 2026.
GLP-1 program scores use the v4.1 methodology and pages read November 20, 2026; peptide and hormone clinics keep their May 2026 profiles and are not part of that ranking.